Jefferies (NYSE:JEF) analyst Andrew Tsai maintained a Buy rating on Xenon (NASDAQ:XENE) on Saturday, setting a price target of $50, which is approximately 48.54% above the present share price of $33.66.
Tsai expects Xenon to post earnings per share (EPS) of -$0.51 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Xenon, with an average price target of $44.33.
The analysts price targets range from a high of $50 to a low of $34.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.22 million and a net profit of -$22.5 million. The company's market cap is $1.73 billion.
According to TipRanks.com, Jefferies analyst Andrew Tsai is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 6.1% and a 50.00% success rate.
Xenon Pharmaceuticals , Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.